CTIS.eu › Cities › Netherlands › Maastricht
Maastricht
Netherlands
321 total trials
157 recruiting
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
2023-505220-57-03
5
2022-05-09
Predicted severe acute pancreatitis
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
2024-513797-22-00
5
2022-03-09
HER2 positive esophageal adenocarcinoma
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
2023-507230-24-00
4
2021-02-17
Cervical cancer
2023-508722-99-00
4
2020-11-19
Vulvar cancer
2024-512526-28-00
5
2020-10-28
Locally recurrent rectal cancer
2023-505449-18-00
4
2020-07-23
Patients with relapsed CLL
2024-515625-29-00
5
2020-06-16
Apnea of prematurity
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
2024-514020-16-00
6
2018-03-14
Post-craniotomy headache
2024-516196-32-00
5
2017-01-01
breast cancer
2023-509152-33-00
4
2016-07-25
Advanced solid tumor
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
2024-510849-34-00
4
2025-02-04
Eosinophilic Esophagitis
2024-516890-63-00
4
2025-01-21
Fibromyalgia
2024-511378-60-00
5
2024-12-11
Myotonic Dystrophy Type 1
2024-517467-23-00
5
2024-11-29
steroid sensitive idiopathic nephrotic syndrome
2023-505989-29-00
5
2024-11-21
Extensive stage small cell lung cancer (ES-SCLC)
Showing 169–192 of 321 trials